***Background.*** Rapid identification of organism and resistance is paramount for targeted treatment in serious blood stream-infections (BSI). Verigene® Gram-Negative Blood Culture Test (BC-GN) is a multiplex, automated nucleic acid test for the identification of a broad panel of Gram-negative (GN) organisms and resistance markers from blood culture bottle positivity with a turnaround time of approximately 2 hours. We evaluated the Verigene® BC-GN assay in combination with theoretical antimicrobial stewardship team (AST) intervention in GN BSIs.

***Methods.*** Clinical isolates from adult patients at the University Maryland Medical Center with GN bacteremia from January 2012 to June 2012 were included. Blood culture bottles were spiked with clinical isolates and processed by Verigene® BC-GN. AST reviewed charts along with Verigene® result and recommended antibiotics using derived algorithms. The time interval included in analysis was time of Gram stain report until 48 hours after susceptibility results. The intervention group\'s (Verigene® with AST) antibiotic recommendation was theoretically implemented at 3 hours from actual Gram stain report, and compared with the control group\'s actual antibiotic administration times obtained from the chart, using Student\'s t-test.

***Results.*** A total of 117 isolates were tested, demonstrating 97.6% sensitivity, 99.6% specificity and overall concordance rate of 95.7% (112/117) for organism identification. Half of the *Enterobacteriaceae* isolates resistant or intermediate to ceftriaxone were detected as CTX-M (5/10) and all of the MDR *A. baumannii* were detected as OXA (7/7). The intervention group had a significantly shorter mean duration to both effective (1.4 vs 6.6 hours, P \< 0.01) and optimal (6.7 vs 47.7 hours, P \< 0.01) antibiotic therapy. Using proportional hazards regression, we found that the intervention group was significantly more likely to receive timely optimal antibiotic therapy compared to controls (hazard ratio 1.5, P = 0.01).

***Conclusion.*** Our study demonstrated a potential decreased time to both effective and optimal antibiotic therapy in GN BSI using combined intervention of rapid testing and AST recommendation. Prospective studies are needed to further validate this strategy.
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